Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven M Horwitz

Showing results (81-90 of 208) with videos related to

Pageof 21
Sort By:
Blood|August 9, 2003
Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphomaSteven M Horwitz, Robert S Negrin, Karl G Blume, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2014
Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I studyMichelle A Fanale, Steven M Horwitz, Andres Forero-Torres, et al.
Haematologica|July 18, 2024
Polytypic B cells, monotypic/monoclonal B-cell proliferations, and neoplastic T cells diverge from <i>TET2</i>-/<i>DNMT3A</i>-mutant clonal hematopoiesis in follicular helper T-cell lymphomasNatasha E Lewis, Kseniya Petrova-Drus, Rohan Sardana, et al.
American Journal of Hematology|March 22, 2019
Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registryRobert N Stuver, Niloufer Khan, Marc Schwartz, et al.
Journal of the American Academy of Dermatology|February 1, 2019
Role of imaging in low-grade cutaneous B-cell lymphoma presenting in the skinMeenal K Kheterpal, Julia Dai, Shamir Geller, et al.
Cancer|June 22, 2010
A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: a multicenter clinicopathologic experience and new prognostic scoreAdrienne A Phillips, Iuliana Shapira, Robert D Willim, et al.
Hematological Oncology|July 13, 2016
Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphomaBarbara Pro, Steven M Horwitz, H Miles Prince, et al.
American Journal of Hematology|February 18, 2011
Prognostic factors in patients with HIV-associated peripheral T-cell lymphoma: a multicenter studyJorge J Castillo, Brady E Beltran, Michele Bibas, et al.
CA: a Cancer Journal for Clinicians|June 29, 2026
Extranodal natural killer/T-cell lymphoma: From fatal to curableJie Xiong, Yok-Lam Kwong, Laurence de Leval, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2012
Phase II study of bendamustine in relapsed and refractory Hodgkin lymphomaAlison J Moskowitz, Paul A Hamlin, Miguel-Angel Perales, et al.
Pageof 21

Showing results (81-90 of 208) with videos related to

Sort By:
Pageof 21
Blood|August 9, 2003
Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphomaSteven M Horwitz, Robert S Negrin, Karl G Blume, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2014
Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I studyMichelle A Fanale, Steven M Horwitz, Andres Forero-Torres, et al.
Haematologica|July 18, 2024
Polytypic B cells, monotypic/monoclonal B-cell proliferations, and neoplastic T cells diverge from <i>TET2</i>-/<i>DNMT3A</i>-mutant clonal hematopoiesis in follicular helper T-cell lymphomasNatasha E Lewis, Kseniya Petrova-Drus, Rohan Sardana, et al.
American Journal of Hematology|March 22, 2019
Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registryRobert N Stuver, Niloufer Khan, Marc Schwartz, et al.
Journal of the American Academy of Dermatology|February 1, 2019
Role of imaging in low-grade cutaneous B-cell lymphoma presenting in the skinMeenal K Kheterpal, Julia Dai, Shamir Geller, et al.
Cancer|June 22, 2010
A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: a multicenter clinicopathologic experience and new prognostic scoreAdrienne A Phillips, Iuliana Shapira, Robert D Willim, et al.
Hematological Oncology|July 13, 2016
Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphomaBarbara Pro, Steven M Horwitz, H Miles Prince, et al.
American Journal of Hematology|February 18, 2011
Prognostic factors in patients with HIV-associated peripheral T-cell lymphoma: a multicenter studyJorge J Castillo, Brady E Beltran, Michele Bibas, et al.
CA: a Cancer Journal for Clinicians|June 29, 2026
Extranodal natural killer/T-cell lymphoma: From fatal to curableJie Xiong, Yok-Lam Kwong, Laurence de Leval, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2012
Phase II study of bendamustine in relapsed and refractory Hodgkin lymphomaAlison J Moskowitz, Paul A Hamlin, Miguel-Angel Perales, et al.
Pageof 21